Pharmaceuticals
1xbet 리뷰s Releases
News releases related to 1xbet 리뷰
2021
2020
2018
2017
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant 1xbet 리뷰 Japanese Government Grants Award for the First Time
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant 1xbet 리뷰 (MDR-TB) in High-Burden Countries(PDF: 467.1 KB)
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant 1xbet 리뷰 (MDR-TB) in Russia and CIS Countries(PDF: 99.9 KB)
Pharmaceuticals
1xbet 리뷰 to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
2016
2015
Pharmaceuticals
Winner Announced for the 2015 Young Innova1xbet 리뷰r in TB Research Award
Pharmaceuticals
Efficacy Results of 1xbet 리뷰's Delamanid (Deltyba™) for Extensively Drug-Resistant 1xbet 리뷰 (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
The Union and 1xbet 리뷰 Open Nominations for 2ndGlobal TB Research & Innovation Award
2014
Pharmaceuticals
A Change in the Treatment of Multidrug-Resistant 1xbet 리뷰 Begins New Anti1xbet 리뷰 Drug Deltyba®in 50 mg Tablets, Available 1xbet 리뷰 Patients in Japan Starting September 26
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of 1xbet 리뷰 In JapanDeltyba®(delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant 1xbet 리뷰 (MDR-TB)
Pharmaceuticals
1xbet 리뷰 Wins European Marketing Authorization for Deltyba™(delamanid)
2013
Pharmaceuticals
CHMP Recommends 1xbet 리뷰's Deltyba™(delamanid) for EU Approval for Treatment of Multidrug-Resistant 1xbet 리뷰 (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Pharmaceuticals